Skip to main content

HOPA Abstracts

Operational and Financial Impact of Electronic Medical Record–Integrated Biomarker Testing Workflows on Specialty Pharmacy in Non–Small Cell Lung Cancer

Abstract #CR21

Kelsey Schildknecht, PharmD; Lauren Gilmer, PharmD

Oxaliplatin Desensitization—A Promising Approach for Patients With Cancer and Hypersensitivity Reactions: Real-World Experience From Vietnam

Abstract #LB01

Le Trang Nguyen

Infusion Pharmacist–Driven Romiplostim Dosing Protocol to Optimize Efficiency in an Outpatient Hematology and Oncology Cancer Center

Abstract #LB02

Ashley Jones, PharmD, BCOP; Hetalkumari Patel, PharmD, BCOP; Kailee Gaines, PharmD, BCOP

Pharmacist-Led Management of Vorasidenib in Patients With Isocitrate Dehydrogenase Mutation–Positive Gliomas

Abstract #LB03

Marie Noelle Bate Baiyee, PharmD; Mary Hilliger, PharmD; Bilge Parlakkilic, PharmD

Building Real-World Evidence Through the HERO Consortium: A Pharmacist-Led Multicenter Initiative

Abstract #LB04

Ila M. Saunders, PharmD, BCOP; Sarah Profitt, PharmD, BCOP

Hybrid Observation Model for Bispecific T-Cell Engager

Abstract #LB05

Alyssa Cendagorta, PharmD, BCOP

Pharmacist and Nurse Preferences for Preparing Large-Volume Subcutaneous Oncology Drugs During a Patient Capacity Crisis in the United Kingdom: A Discrete-Choice Study Comparing Manual Syringe Versus an On-Body Injector

Abstract #LB06

Haydon DuMond, PharmD

Optimizing Iron Dextran Infusion Protocols to Enhance Efficiency and Patient Throughput in an Outpatient Infusion Center: A Process Improvement Initiative

Abstract #CR01

Minhee Kang, PharmD, BCPS, BCOP; Richard Verstraete, RN

Characteristics and Dosing Patterns of US Patients Diagnosed With HR-Positive/HER2-Negative Early Breast Cancer Initiating Abemaciclib at a Lower Dose Than the Approved 150 mg Twice Daily

Abstract #CR02

Andrea LeVoir, PharmD; Laura Spring, MD; Wambui Gathirua-Mwangi, PhD; Sangmi Kim, PhD; Zhanglin Lin Cui, PhD; Samuel Whipple, MPH, et al.

Clinical Characteristics and Treatment Persistence in US Patients With HR-Positive/HER2-Negative, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

Abstract #CR03

Erich Brechtelsbauer, PharmD, MS; Kathryn Hudson, MD; Wambui Gathirua-Mwangi, PhD; Zhanglin Lin Cui; Brenda Grimes, PhD; Astra M. Liepa, PharmD, et al.

Page 3 of 15
Results 21 - 30 of 146